• 1
    Farrell RJ, Peppercorn MA. Ulcerative colitis. Lancet 2002; 359: 33140.
  • 2
    Gionchetti P, Rizzello F, Habal F, et al. Standard treatment of ulcerative colitis. Dig Dis 2003; 21: 15767.
  • 3
    Frieri G, Giacomelli R, Pimpo M, et al. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut 2000; 47: 4104.
  • 4
    Wilding IR, Kenyon CJ, Hooper G. Gastrointestinal spread of oral prolonged-release mesalazine microgranules (Pentasa) dosed as either tablets or sachet. Aliment Pharmacol Ther 2000; 14: 1639.
  • 5
    Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996; 334: 8418.
  • 6
    Egan LJ, Sandborn WJ. Drug therapy of inflammatory bowel disease. Drugs Today (Barc) 1998; 34: 43146.
  • 7
    van Hees PA, van Tongeren JH. Compliance to therapy in patients on a maintenance dose of sulfasalazine. J Clin Gastroenterol 1982; 4: 3336.
  • 8
    Moody GA, Jayanthi V, Probert CS, Mac Kay H, Mayberry JF. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996; 8: 117983.
  • 9
    Kane S. Patient compliance and outcomes. Inflamm Bowel Dis 1999; 5: 1347.
  • 10
    Moum B. Medical treatment: does it influence the natural course of inflammatory bowel disease? Eur J Intern Med 2000; 11: 197203.
  • 11
    Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 1918.
  • 12
    Kruis W, Bar-Meir S, Feher J, et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 2003; 1: 3643.
  • 13
    Kruis W, Schreiber S, Theuer D, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut 2001; 49: 7839.
  • 14
    Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2002(4): CD000544. Review.
  • 15
    Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2003(3): CD000543. Review.
  • 16
    Loftus EVJr, Kane SV, Bjorkman D. Systematic review: Short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2004; 19: 17989.
  • 17
    Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323: 122833.
  • 18
    Ransohoff DF. Colon cancer in ulcerative colitis. Gastroenterology 1988; 94: 108991.
  • 19
    Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000; 14: 14553.
  • 20
    Allgayer H. Review article: Mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18 (Suppl. 2): 104.
  • 21
    Reinacher-Schick A, Seidensticker F, Petrasch S, et al. Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. Endoscopy 2000; 32: 24554.
  • 22
    Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 1993; 88: 118897.
  • 23
    Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 16259.
  • 24
    AWMF-Leitlinien-Register Nr. 021/009. Leitlinie der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten, 2000. Accessed at
  • 25
    Schölmerich J, Stange EF. Chronic inflammatory bowel diseases: drug therapy standards and trends. Internist (Berl) 2001; 42: 5338, 540–3.
  • 26
    Herrlinger K, Fellermann K, Stange EF. Standard therapy of ulcerative colitis. Evidence- and consensus-based recommendations. Internist (Berl) 2002; 43: 13678, 1371–5.
  • 27
    Wilding IR, Behrens C, Tardif SJ, Wray H, Bias P, Albrecht W. Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects. Aliment Pharmacol Ther 2003; 17: 115362.
  • 28
    Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989; 298: 826.
  • 29
    Casellas F, Alcala MJ, Prieto L, Miro JR, Malagelada JR. Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire. Am J Gastroenterol 2004; 99: 45761.
    Direct Link:
  • 30
    Lorenz R, Olbert P, Born P. Factor XIII in chronic inflammatory bowel diseases. Semin Thromb Hemost 1996; 22: 4515.
  • 31
    FDA. Points to consider. Division of anti-infective drug products. Clinical Development and Labelling of Anti-infective Drug Products, 1995. Report No. 2: p.20.
  • 32
    Kruis W, Brandes JW, Schreiber S, et al. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Aliment Pharmacol Ther 1998; 12: 70715.
  • 33
    Farup PG. Compliance with anti-ulcer medication during short-term healing phase clinical trials. Aliment Pharmacol Ther 1992; 6: 17986.
  • 34
    Evans L, Spelman M. The problem of non-compliance with drug therapy. Drugs 1983; 25: 6376.
  • 35
    Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997; 92: 186771.
  • 36
    Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology 1993; 104: 1293301.
  • 37
    Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 32737.
  • 38
    Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 18814.
  • 39
    Farup PG, Hinterleitner TA, Lukas M, et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis 2001; 7: 23742.
  • 40
    Rubin G, Hungin AP, Chinn D, Dwarakanath AD, Green L, Bates J. Long-term aminosalicylate therapy is under-used in patients with ulcerative colitis: a cross-sectional survey. Aliment Pharmacol Ther 2002; 16: 188993.
  • 41
    Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology 2004; 126: 158292.
  • 42
    Courtney ED, Melville DM, Leicester RJ. Review article: Chemoprevention of colorectal cancer. Aliment Pharmacol Ther 2004; 19: 124.
  • 43
    Croog VJ, Ullman TA, Itzkowitz SH. Chemoprevention of colorectal cancer in ulcerative colitis. Int J Colorectal Dis 2003; 18: 392400.
  • 44
    Ryan BM, Russel MG, Langholz E, Stockbrugger RW. Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow. Am J Gastroenterol 2003; 98: 16827.
    Direct Link:
  • 45
    Caprilli R, Cottone M, Tonelli F, et al. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial. Aliment Pharmacol Ther 2003; 17: 51723.
  • 46
    Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77: 84769.